Zhaoke Ophthalmology (HKG:6622) said China's National Medical Products Administration (NMPA) gave the marketing authorization for its Glaucoma eyedrops, Bimatoprost, according to a Thursday filing with the Hong Kong bourse.
Bimatoprost are preservative-free single-dose drops used to lower the intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
The company's stocks were up by almost 3% in the early trading.
Price (HKD): $1.39, Change: $+0.040, Percent Change: +2.96%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.